Investigating a drug to reduce lung damage from chlorine gas exposure
Identification of AMD3100 (Plerixafor) as a lead compound for chlorine toxicity
This study is looking at how breathing in chlorine gas can harm the lungs and how a certain drug called AMD3100 might help protect against that damage, so it's for anyone interested in finding better treatments for lung injuries caused by chlorine exposure.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Florida International University NIH-funded |
| Lab location | 1 site (Miami, United States) |
| Project ID | NIH-11116590 on NIH RePORTER |
What this research studies
This research focuses on understanding how chlorine gas exposure affects the lungs and the immune response. It examines the role of a specific signaling pathway involving the SDF-1/CXCR4 axis, which is believed to contribute to lung injury after chlorine exposure. The study aims to test the FDA-approved drug AMD3100 (Plerixafor) to see if it can inhibit this pathway and reduce lung damage. By using animal models, the researchers will explore the optimal dosage and mechanisms of action of the drug in the context of chlorine toxicity.
Who could benefit from this research
Good fit: Ideal candidates for this research would be individuals who have been exposed to chlorine gas or are at risk of such exposure.
Not a fit: Patients who have not been exposed to chlorine gas or have pre-existing severe lung conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly reduce lung injury and improve survival rates for individuals exposed to chlorine gas.
How similar studies have performed: While the specific application of AMD3100 for chlorine toxicity is novel, similar approaches targeting the SDF-1/CXCR4 axis have shown promise in other contexts.
Where this research is happening
Miami, United States
- Florida International University — Miami, United States (Active)
Researchers
- Principal investigator: Aggarwal, Saurabh — Florida International University
- Study coordinator: Aggarwal, Saurabh
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.